Hormone Resistant Prostate Cancer Completed Phase 2 Trials for Ganetespib (DB12047)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01270880Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyTreatment